Clarithromycin
- Generic Name
- Clarithromycin
- Brand Names
- Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C38H69NO13
- CAS Number
- 81103-11-9
- Unique Ingredient Identifier
- H1250JIK0A
- Background
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
- Indication
An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
Clarithromycin is indicated in combination with vonoprazan and amoxicillin as co-packaged triple therapy to treat Helicobacter pylori (H. pylori) infection in adults.
- Associated Conditions
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections
- Associated Therapies
- -
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma
- Conditions
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 96
- Registration Number
- NCT00003151
- Locations
- 🇬🇧
Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, United Kingdom
🇬🇧Royal United Hospital, Bath, England, United Kingdom
🇬🇧Royal Free Hospital, Hampstead, London, England, United Kingdom
Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach
- Conditions
- Interventions
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00002682
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center Orlando, Orlando, Florida, United States
Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Lymphoma Trials Office
- Target Recruit Count
- 200
- Registration Number
- NCT00003617
- Locations
- 🇬🇧
Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, United Kingdom
🇬🇧Leeds Teaching Hospital Trust, Leeds, England, United Kingdom
🇬🇧Essex County Hospital, Colchester, England, United Kingdom
Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT00006219
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Abbott
- Registration Number
- NCT00002331
- Locations
- 🇺🇸
George Washington Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Dr Margaret Fischel, Miami, Florida, United States
🇺🇸Kaiser Permanente Med Ctr, San Francisco, California, United States
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 246
- Registration Number
- NCT00001058
- Locations
- 🇺🇸
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇺🇸Methodist Hosp. of Indiana, Indianapolis, Indiana, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002140
- Locations
- 🇺🇸
Dr Milton Estes, Mill Valley, California, United States
🇺🇸Santa Clara Valley Med Ctr, San Jose, California, United States
🇺🇸Whitman - Walker Clinic, Washington, District of Columbia, United States
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia
- Target Recruit Count
- 450
- Registration Number
- NCT00002101
- Locations
- 🇺🇸
TheraFirst Med Ctrs Inc, Fort Lauderdale, Florida, United States
🇺🇸Dr Frank Tornaka, Fort Lauderdale, Florida, United States
🇺🇸Gary Richmond MD, Fort Lauderdale, Florida, United States
Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Anderson Clinical Research
- Registration Number
- NCT00002192
- Locations
- 🇺🇸
Hampton Roads Med Specialists, Hampton, Virginia, United States
Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-10-31
- Target Recruit Count
- 24
- Registration Number
- NCT00001039
- Locations
- 🇺🇸
UMDNJ - New Jersey Med School / Cooper Hosp, Camden, New Jersey, United States
🇺🇸Univ of Maryland at Baltimore, Baltimore, Maryland, United States
🇺🇸Richmond AIDS Consortium, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.